SCHEMBL6314946

SCHEMBL6314946

CC(=O)C(C)Oc1ccc2[nH]c(C)c(C(=O)O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
AKR1C2 P52895 1/20 0.44
CYP2C9 P11712 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GAA P10253 4/20 0.42
KDM4E B2RXH2 6/20 0.41
HPGD P15428 2/20 0.41
THRB P10828 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
TDP1 Q9NUW8 3/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.39
PTPN5 P54829 1/20 0.39
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315167 0.82 KDM4E (0.50) ALDH1A1AKR1C2LMNASMN1; SMN2GAA
SCHEMBL6323335 0.81 GAA (0.50) ALDH1A1CYP2C9LMNASMN1; SMN2GAA
SCHEMBL1434196 0.81 ALDH1A1 (0.67) ALDH1A1AKR1C2GAAKDM4EHPGD
SCHEMBL6656803 0.78 GAA (0.57) ALDH1A1CYP2C9LMNASMN1; SMN2GAA
SCHEMBL27580214 0.77 ALDH1A1 (0.46) ALDH1A1AKR1C2LMNASMN1; SMN2GAA
SCHEMBL18932673 0.75 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2GAAKDM4EHPGD
SCHEMBL3389079 0.74 TRPM8 (0.61) ALDH1A1CYP2C9LMNASMN1; SMN2GAA
SCHEMBL27598425 0.74 SMN1; SMN2 (0.48) ALDH1A1AKR1C2LMNASMN1; SMN2GAA
SCHEMBL3385819 0.73 GAA (0.66) ALDH1A1CYP2C9LMNAGAAKDM4E
SCHEMBL6315222 0.73 ALDH1A1 (0.56) ALDH1A1AKR1C2LMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951848-B2 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC., (US) 2005-10-04 US disclosed
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
EP-1377549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR Millennium Pharmaceuticals, Inc. (US) 2004-01-07 EP disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 ALDH1A1 672/4885AKR1C2 261/4885CYP2C9 1057/4885
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 ALDH1A1 956/4885AKR1C2 314/4885CYP2C9 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.